ELEKTA SELECTED TO SUPPLY THE ROYAL MARSDEN HOSPITAL IN LONDON, UK, WITH ADDITIONAL ADVANCED RADIATION THERAPY SYSTEMS

ELEKTA SELECTED TO SUPPLY THE ROYAL MARSDEN HOSPITAL IN LONDON, UK, WITH
ADDITIONAL ADVANCED RADIATION THERAPY SYSTEMS

PRESS RELEASE	
Stockholm, Sweden, June 29, 2007

Elekta, a world leader in advanced radiation therapy and radiosurgery
treatments, has recently been awarded an order to supply two Elekta Synergy®
systems to The Royal Marsden NHS Foundation Trust. Included within the order is
one HexaPOD™ 6D robotic patient positioning system and a full MOSAIQ™
electronical medical records and networking software suite.

Elekta Synergy® is the most advanced and clinically proven cancer treatment
system with intensity modulated radiation therapy (IMRT) and advanced 3D image
guided radiation therapy (IGRT), allowing clinicians to both image and treat
patients in the same frame of reference, at the time of treatment. This
innovative new radiation therapy treatment system directly addresses the three
most persistent and significant problems in modern radiation therapy: external
patient movement, internal organ motion, and errors in overeall patient set-up.
The result is unmatched clinical confidence for precise tumor targeting,
enabling more aggressive treatment of tumors while minimizing damage to
surrounding healthy tissue.

A top ranked NHS trust with five IGRT systems from Elekta

The Royal Marsden Hospital was the first hospital in the world dedicated to
cancer treatment and research into the causes of cancer. Today the hospital with
its academic partner, The Institute of Cancer Research, form the largest
comprehensive cancer centre in Europe with over 40,000 patients from the UK and
abroad seen each year.

The Royal Marsden NHS Foundation Trust is ranked as one of the top two NHS
trusts in the country in the new NHS national performance rankings.

Previously equipped with three Elekta Synergy systems in routine clinical
operation, the Trust has now decided to further enhance its capacity and
capabilities with additional treatment systems and software solutions from
Elekta."The purchase of these two additional Elekta Synergy systems will make The Royal
Marsden one of the best equipped Radiotherapy Centers in the UK, with five fully
operational IGRT treatment systems from Elekta”, commented Jim Warrington, Head
of Radiotherapy Physics at The Royal Marsden Hospital. “After extensive
evaluation of available technology, it became apparent to the evaluation team
that Elekta Synergy is an extremely effective 3D IGRT solution. When this is
used in conjunction with a variety of intensity modulated and arc based delivery
techniques, there is a very exciting prospect of delivering the most advanced
radiotherapy treatments in the world. These developments should both improve
patient outcomes and quality of life without compromising patient throughput
within the department", Warrington concluded.

Apparent need for additional treatment capacity in the UK

Although the UK National Health Services has made extensive investments during
this decade in additional capacity for radiation therapy, there is a continued
strong pressure for further improvement of treatment capacity throughout the
nation.

A recent scientific article concluded that “To secure adequate access to
treatment and optimal dose fractionation, substantial increases in radiotherapy
activity of 92% in England, 61% in Scotland and 97% in Wales are required.
Achieving this will require a planned programme of investment in staff, training
and equipment.”(1)

The National Radiotherapy Advisory Group (NRAG) recently submitted a report to
the UK Government concluding: “There is a general consensus among experts that
the projected need for radiotherapy was significantly underestimated 15-20 years
ago. There is a large gap (63%) between current activity levels and optimal
treatment levels, if radiotherapy were to be given to all who might benefit. The
position is set to worsen as cancer incidence increases with the ageing
population.”(2)

At present, the NHS delivers around 30,000 radiation therapy fractions per
million inhabitants. NRAG strongly recommends that NHS radiotherapy services
should be developed to deliver up to 54,000 fractions per million inhabitants
throughout the country by 2016.

“Through our technology leadership in advanced radiation therapy, Elekta has
developed strong relationships with The Royal Marsden and many other NHS Trusts.
We are proud to be a part of the ongoing efforts to develop new and innovative
treatment methods as well as improve treatment capacity in the UK”, commented
David Miles, Elekta's UK Business Unit Managing Director 


(1) Radiotherapy Dose Fractionation, Access and Waiting Times in the Countries
of the UK in 2005 - Williams, M. V. et al. Clinical Oncology, 2007.

(2) Radiotherapy: developing a world class service for England - Report to
Ministers from National Radiotherapy Advisory Group, February 2007

******


For further information, please contact:

Peter Ejemyr, Group VP Corporate Communications, Elekta AB
Tel: +46 733 611 000 (mobile), e-mail: peter.ejemyr@elekta.com  

About Elekta

Elekta is an international medical-technology Group, providing meaningful
clinical solutions, comprehensive information systems and services for improved
cancer care and management of brain disorders. All of Elekta's solutions employ
non-invasive or minimally invasive techniques and are therefore clinically
effective, gentle on the patient and cost-effective. 

Clinical solutions include among others Leksell Gamma Knife® for non-invasive
treatment of brain disorders and Elekta Synergy® for image guided radiation
therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April
2005, the Elekta Group is the world's largest supplier of oncology software. 

Elekta's systems and solutions are used at over 4,000 hospitals around the world
to treat cancer and manage clinical operations as well as to diagnose and treat
brain disorders, including tumors, vascular malformations and functional
disorders. 

With approx. 2,000 employees, Elekta's corporate headquarter is located in
Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange
under the ticker EKTAb. For more information about Elekta, please visit
www.elekta.com.